Orgenesis Inc.

At this time, all participants have been placed on a listen-only mode.

Good morning, ladies and gentlemen, and welcome to the Origenesis Fiscal 2020 Year-End Conference Call. At this time, all participants have been placed on a listen-only mode, and the floor will be open for questions and comments after the presentation. It is now my pleasure to turn the floor over to your host, David Wallman, Investor Relations. Sir, the floor is yours.

Thank you. Good morning, everyone, and welcome to your Genesis year-end business update conference call. On the call with us this morning are Varad Kaplan, Chief Executive Officer, and Neil Reisinger, Chief Financial Officer. If you have any questions after the call or would like any additional information about the company, please contact Crescendo Communications at 212-671-1020. This conference call contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 as amended, and Section 21E of the Securities and Exchange Act of 1934 as amended. These forward-looking statements involve substantial uncertainties and risks, are based upon our current expectations, estimates, and projections, and we reflect our beliefs and assumptions based on information available to us at the date of this conference call. We caution listeners that forward-looking statements are predictions based on our current expectations about future events. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and assumptions that are difficult to predict. Our actual results, performance, or achievements could differ materially from those expressed or implied by the forward-looking statements as a result of a number of factors, including but not limited to our ability to further develop our products, Our reliance on our ability to grow our point of care cell therapy platform, our ability to develop cell-based antiviral technologies, our ability to effectively use the net proceeds from the sale of master cell, our ability to achieve and maintain overall profitability, the development of our point of care strategy, the sufficiency of working capital to realize our business plans, our partner's ability to develop therapies based on our point of care cell therapy platform. Technology not functioning as expected, our ability to retain key employees, our ability to satisfy the rigorous regulatory requirements for new procedures and therapies, our competitors developing better achievable alternatives, the impact of COVID-19 on our operations, and the risks and uncertainties discussed under the heading risk factors in item 1A of our annual report on Form 10-K for the fiscal year ended December 31st, 2019, and in our other filings with the Securities and Exchange Commission, we undertake no obligation to revise or update any forward-looking statements for any reason. I'd now like to turn the call over to Ms. Varad Kaplan. Please go ahead, Varad.